ID   F16P1_HUMAN             Reviewed;         338 AA.
AC   P09467; O75571; Q53F94; Q96E46;
DT   01-JUL-1989, integrated into UniProtKB/Swiss-Prot.
DT   02-NOV-2010, sequence version 5.
DT   15-MAR-2017, entry version 190.
DE   RecName: Full=Fructose-1,6-bisphosphatase 1;
DE            Short=FBPase 1;
DE            EC=3.1.3.11;
DE   AltName: Full=D-fructose-1,6-bisphosphate 1-phosphohydrolase 1;
DE   AltName: Full=Liver FBPase;
GN   Name=FBP1; Synonyms=FBP;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT LYS-218.
RX   PubMed=2842796; DOI=10.1073/pnas.85.18.6904;
RA   Solomon D.H., Raynal M.-C., Tejwani G.A., Cayre Y.E.;
RT   "Activation of the fructose 1,6-bisphosphatase gene by 1,25-
RT   dihydroxyvitamin D3 during monocytic differentiation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 85:6904-6908(1988).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], PROTEIN SEQUENCE OF 2-11, MUTAGENESIS OF
RP   ASP-119 AND ASP-122, AND VARIANT LYS-218.
RC   TISSUE=Liver;
RX   PubMed=8387495;
RA   El-Maghrabi M.R., Gidh-Jain M., Austin L.R., Pilkis S.J.;
RT   "Isolation of a human liver fructose-1,6-bisphosphatase cDNA and
RT   expression of the protein in Escherichia coli. Role of Asp-118 and
RT   Asp-121 in catalysis.";
RL   J. Biol. Chem. 268:9466-9472(1993).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT LYS-218.
RC   TISSUE=Kidney, Liver, and Monocyte;
RX   PubMed=8135811; DOI=10.1006/bbrc.1994.1283;
RA   Kikawa Y., Inuzuka M., Takano T., Shigematsu Y., Nakai A.,
RA   Yamamoto Y., Jin B.Y., Koga J., Taketo A., Sudo M.;
RT   "cDNA sequences encoding human fructose 1,6-bisphosphatase from
RT   monocytes, liver and kidney: application of monocytes to molecular
RT   analysis of human fructose 1,6-bisphosphatase deficiency.";
RL   Biochem. Biophys. Res. Commun. 199:687-693(1994).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT LYS-218.
RC   TISSUE=Liver;
RX   PubMed=7558035; DOI=10.1006/geno.1995.1085;
RA   El-Maghrabi M.R., Lang A.J., Jiang W., Yamagata K., Stoffel M.,
RA   Takeda J., Fernald A.A., le Beau M.M., Bell G.I., Baker L.,
RA   Pilkis S.J.;
RT   "Human fructose-1,6-bisphosphatase gene (FBP1): exon-intron
RT   organization, localization to chromosome bands 9q22.2-q22.3, and
RT   mutation screening in subjects with fructose-1,6-bisphosphatase
RT   deficiency.";
RL   Genomics 27:520-525(1995).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA], CHARACTERIZATION, AND VARIANT LYS-218.
RC   TISSUE=Lung;
RX   PubMed=10222032; DOI=10.1006/abbi.1999.1120;
RA   Skalecki K., Rakus D., Wisniewski J.R., Kolodziej J., Dzugaj A.;
RT   "cDNA sequence and kinetic properties of human lung fructose(1,
RT   6)bisphosphatase.";
RL   Arch. Biochem. Biophys. 365:1-9(1999).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT LYS-218.
RC   TISSUE=Thymus;
RA   Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S.;
RL   Submitted (APR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS LYS-218; ILE-233 AND
RP   LEU-255.
RG   NIEHS SNPs program;
RL   Submitted (DEC-2004) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164053; DOI=10.1038/nature02465;
RA   Humphray S.J., Oliver K., Hunt A.R., Plumb R.W., Loveland J.E.,
RA   Howe K.L., Andrews T.D., Searle S., Hunt S.E., Scott C.E., Jones M.C.,
RA   Ainscough R., Almeida J.P., Ambrose K.D., Ashwell R.I.S.,
RA   Babbage A.K., Babbage S., Bagguley C.L., Bailey J., Banerjee R.,
RA   Barker D.J., Barlow K.F., Bates K., Beasley H., Beasley O., Bird C.P.,
RA   Bray-Allen S., Brown A.J., Brown J.Y., Burford D., Burrill W.,
RA   Burton J., Carder C., Carter N.P., Chapman J.C., Chen Y., Clarke G.,
RA   Clark S.Y., Clee C.M., Clegg S., Collier R.E., Corby N., Crosier M.,
RA   Cummings A.T., Davies J., Dhami P., Dunn M., Dutta I., Dyer L.W.,
RA   Earthrowl M.E., Faulkner L., Fleming C.J., Frankish A.,
RA   Frankland J.A., French L., Fricker D.G., Garner P., Garnett J.,
RA   Ghori J., Gilbert J.G.R., Glison C., Grafham D.V., Gribble S.,
RA   Griffiths C., Griffiths-Jones S., Grocock R., Guy J., Hall R.E.,
RA   Hammond S., Harley J.L., Harrison E.S.I., Hart E.A., Heath P.D.,
RA   Henderson C.D., Hopkins B.L., Howard P.J., Howden P.J., Huckle E.,
RA   Johnson C., Johnson D., Joy A.A., Kay M., Keenan S., Kershaw J.K.,
RA   Kimberley A.M., King A., Knights A., Laird G.K., Langford C.,
RA   Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C., Lloyd D.M.,
RA   Lovell J., Martin S., Mashreghi-Mohammadi M., Matthews L., McLaren S.,
RA   McLay K.E., McMurray A., Milne S., Nickerson T., Nisbett J.,
RA   Nordsiek G., Pearce A.V., Peck A.I., Porter K.M., Pandian R.,
RA   Pelan S., Phillimore B., Povey S., Ramsey Y., Rand V., Scharfe M.,
RA   Sehra H.K., Shownkeen R., Sims S.K., Skuce C.D., Smith M.,
RA   Steward C.A., Swarbreck D., Sycamore N., Tester J., Thorpe A.,
RA   Tracey A., Tromans A., Thomas D.W., Wall M., Wallis J.M., West A.P.,
RA   Whitehead S.L., Willey D.L., Williams S.A., Wilming L., Wray P.W.,
RA   Young L., Ashurst J.L., Coulson A., Blocker H., Durbin R.M.,
RA   Sulston J.E., Hubbard T., Jackson M.J., Bentley D.R., Beck S.,
RA   Rogers J., Dunham I.;
RT   "DNA sequence and analysis of human chromosome 9.";
RL   Nature 429:369-374(2004).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Urinary bladder;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 320-338.
RC   TISSUE=Liver;
RX   PubMed=7589895; DOI=10.1046/j.1432-0436.1995.5910051.x;
RA   Bertolotti R., Armbruster-Hilbert L., Okayama H.;
RT   "Liver fructose-1,6-bisphosphatase cDNA: trans-complementation of
RT   fission yeast and characterization of two human transcripts.";
RL   Differentiation 59:51-60(1995).
RN   [11]
RP   FUNCTION.
RX   PubMed=16497803; DOI=10.1210/en.2005-1498;
RA   Lamont B.J., Visinoni S., Fam B.C., Kebede M., Weinrich B.,
RA   Papapostolou S., Massinet H., Proietto J., Favaloro J.,
RA   Andrikopoulos S.;
RT   "Expression of human fructose-1,6-bisphosphatase in the liver of
RT   transgenic mice results in increased glycerol gluconeogenesis.";
RL   Endocrinology 147:2764-2772(2006).
RN   [12]
RP   ENZYME REGULATION, BIOPHYSICOCHEMICAL PROPERTIES, AND MUTAGENESIS OF
RP   GLN-70.
RX   PubMed=17350621; DOI=10.1016/j.febslet.2007.02.051;
RA   Zarzycki M., Maciaszczyk E., Dzugaj A.;
RT   "Glu 69 is essential for the high sensitivity of muscle fructose-1,6-
RT   bisphosphatase inhibition by calcium ions.";
RL   FEBS Lett. 581:1347-1350(2007).
RN   [13]
RP   FUNCTION, TISSUE SPECIFICITY, AND INDUCTION.
RX   PubMed=18375435; DOI=10.2337/db07-1326;
RA   Kebede M., Favaloro J., Gunton J.E., Laybutt D.R., Shaw M., Wong N.,
RA   Fam B.C., Aston-Mourney K., Rantzau C., Zulli A., Proietto J.,
RA   Andrikopoulos S.;
RT   "Fructose-1,6-bisphosphatase overexpression in pancreatic beta-cells
RT   results in reduced insulin secretion: a new mechanism for fat-induced
RT   impairment of beta-cell function.";
RL   Diabetes 57:1887-1895(2008).
RN   [14]
RP   FUNCTION.
RX   PubMed=22517657; DOI=10.2337/db11-1511;
RA   Visinoni S., Khalid N.F., Joannides C.N., Shulkes A., Yim M.,
RA   Whitehead J., Tiganis T., Lamont B.J., Favaloro J.M., Proietto J.,
RA   Andrikopoulos S., Fam B.C.;
RT   "The role of liver fructose-1,6-bisphosphatase in regulating appetite
RT   and adiposity.";
RL   Diabetes 61:1122-1132(2012).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-265, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [16]
RP   X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) IN COMPLEXES WITH MAGNESIUM IONS
RP   AND SUBSTRATE ANALOGS, AND COFACTOR.
RX   PubMed=8382525; DOI=10.1021/bi00058a019;
RA   Zhang Y., Liang J.-Y., Huang S., Ke H., Lipscomb W.N.;
RT   "Crystallographic studies of the catalytic mechanism of the neutral
RT   form of fructose-1,6-bisphosphatase.";
RL   Biochemistry 32:1844-1857(1993).
RN   [17]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) IN COMPLEX WITH
RP   FRUCTOSE-2,6-BISPHOSPHATE; AMP AND ZINC, SUBUNIT, COFACTOR, AND ENZYME
RP   REGULATION.
RX   PubMed=7809062; DOI=10.1073/pnas.91.26.12482;
RA   Xue Y., Huang S., Liang J.-Y., Zhang Y., Lipscomb W.N.;
RT   "Crystal structure of fructose-1,6-bisphosphatase complexed with
RT   fructose 2,6-bisphosphate, AMP, and Zn2+ at 2.0-A resolution: aspects
RT   of synergism between inhibitors.";
RL   Proc. Natl. Acad. Sci. U.S.A. 91:12482-12486(1994).
RN   [18]
RP   X-RAY CRYSTALLOGRAPHY (2.81 ANGSTROMS) IN COMPLEX WITH BENZOXAZOLE
RP   BENZENESULFONAMIDES, SUBUNIT, AND ENZYME REGULATION.
RX   PubMed=16446092; DOI=10.1016/j.bmcl.2006.01.014;
RA   Lai C., Gum R.J., Daly M., Fry E.H., Hutchins C., Abad-Zapatero C.,
RA   von Geldern T.W.;
RT   "Benzoxazole benzenesulfonamides as allosteric inhibitors of fructose-
RT   1,6-bisphosphatase.";
RL   Bioorg. Med. Chem. Lett. 16:1807-1810(2006).
RN   [19]
RP   X-RAY CRYSTALLOGRAPHY (2.95 ANGSTROMS) IN COMPLEX WITH BENZOXAZOLE
RP   BENZENESULFONAMIDES, SUBUNIT, AND ENZYME REGULATION.
RX   PubMed=16442285; DOI=10.1016/j.bmcl.2006.01.015;
RA   von Geldern T.W., Lai C., Gum R.J., Daly M., Sun C., Fry E.H.,
RA   Abad-Zapatero C.;
RT   "Benzoxazole benzenesulfonamides are novel allosteric inhibitors of
RT   fructose-1,6-bisphosphatase with a distinct binding mode.";
RL   Bioorg. Med. Chem. Lett. 16:1811-1815(2006).
RN   [20]
RP   X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) IN COMPLEX WITH AROMATIC
RP   SULFONYLUREA AMP ANALOGS, SUBUNIT, AND ENZYME REGULATION.
RX   PubMed=18650089; DOI=10.1016/j.bmcl.2008.06.103;
RA   Hebeisen P., Kuhn B., Kohler P., Gubler M., Huber W., Kitas E.,
RA   Schott B., Benz J., Joseph C., Ruf A.;
RT   "Allosteric FBPase inhibitors gain 10(5) times in potency when
RT   simultaneously binding two neighboring AMP sites.";
RL   Bioorg. Med. Chem. Lett. 18:4708-4712(2008).
RN   [21]
RP   VARIANTS FBP1D SER-164 AND ASP-177, AND VARIANT ALA-325.
RX   PubMed=9382095; DOI=10.1086/514875;
RA   Kikawa Y., Inuzuka M., Jin B.Y., Kaji S., Koga J., Yamamoto Y.,
RA   Fujisawa K., Hata I., Nakai A., Shigematsu Y., Mizunuma H., Taketo A.,
RA   Mayumi M., Sudo M.;
RT   "Identification of genetic mutations in Japanese patients with
RT   fructose-1,6-bisphosphatase deficiency.";
RL   Am. J. Hum. Genet. 61:852-861(1997).
RN   [22]
RP   VARIANTS FBP1D SER-194 AND ARG-284.
RX   PubMed=12126934; DOI=10.1016/S1096-7192(02)00038-0;
RA   Matsuura T., Chinen Y., Arashiro R., Katsuren K., Tamura T.,
RA   Hyakuna N., Ohta T.;
RT   "Two newly identified genomic mutations in a Japanese female patient
RT   with fructose-1,6-bisphosphatase (FBPase) deficiency.";
RL   Mol. Genet. Metab. 76:207-210(2002).
RN   [23]
RP   VARIANT FBP1D TRP-158.
RX   PubMed=25601412; DOI=10.1007/s10545-014-9804-6;
RA   Lebigot E., Brassier A., Zater M., Imanci D., Feillet F., Therond P.,
RA   de Lonlay P., Boutron A.;
RT   "Fructose 1,6-bisphosphatase deficiency: clinical, biochemical and
RT   genetic features in French patients.";
RL   J. Inherit. Metab. Dis. 38:881-887(2015).
CC   -!- FUNCTION: Catalyzes the hydrolysis of fructose 1,6-bisphosphate to
CC       fructose 6-phosphate in the presence of divalent cations, acting
CC       as a rate-limiting enzyme in gluconeogenesis. Plays a role in
CC       regulating glucose sensing and insulin secretion of pancreatic
CC       beta-cells. Appears to modulate glycerol gluconeogenesis in liver.
CC       Important regulator of appetite and adiposity; increased
CC       expression of the protein in liver after nutrient excess increases
CC       circulating satiety hormones and reduces appetite-stimulating
CC       neuropeptides and thus seems to provide a feedback mechanism to
CC       limit weight gain. {ECO:0000269|PubMed:16497803,
CC       ECO:0000269|PubMed:18375435, ECO:0000269|PubMed:22517657}.
CC   -!- CATALYTIC ACTIVITY: D-fructose 1,6-bisphosphate + H(2)O = D-
CC       fructose 6-phosphate + phosphate.
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420; Evidence={ECO:0000250};
CC       Note=Binds 3 Mg(2+) ions per subunit. {ECO:0000250};
CC   -!- ENZYME REGULATION: Subject to complex allosteric regulation. The
CC       enzyme can assume an active R-state, or an inactive T-state.
CC       Intermediate conformations may exist. AMP acts as allosteric
CC       inhibitor. AMP binding affects the turnover of bound substrate and
CC       not the affinity for substrate. Fructose 2,6-bisphosphate acts as
CC       competitive inhibitor. Fructose 2,6-bisphosphate and AMP have
CC       synergistic effects. {ECO:0000269|PubMed:16442285,
CC       ECO:0000269|PubMed:16446092, ECO:0000269|PubMed:17350621,
CC       ECO:0000269|PubMed:18650089, ECO:0000269|PubMed:7809062}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=2.7 uM for fructose 1,6-biphosphate
CC         {ECO:0000269|PubMed:17350621};
CC         Note=The kinetic constants are determined for the recombinant
CC         enzyme expressed in E.coli.;
CC   -!- PATHWAY: Carbohydrate biosynthesis; gluconeogenesis.
CC   -!- SUBUNIT: Homotetramer. {ECO:0000269|PubMed:16442285,
CC       ECO:0000269|PubMed:16446092, ECO:0000269|PubMed:18650089,
CC       ECO:0000269|PubMed:7809062}.
CC   -!- INTERACTION:
CC       Self; NbExp=12; IntAct=EBI-712740, EBI-712740;
CC       O00499:BIN1; NbExp=4; IntAct=EBI-712740, EBI-719094;
CC       O00757:FBP2; NbExp=14; IntAct=EBI-712740, EBI-719781;
CC   -!- TISSUE SPECIFICITY: Expressed in pancreatic islets.
CC       {ECO:0000269|PubMed:18375435}.
CC   -!- INDUCTION: Up-regulated in pancreatic islets of individuals with
CC       type 2 diabetes. {ECO:0000269|PubMed:18375435}.
CC   -!- DISEASE: Fructose-1,6-bisphosphatase deficiency (FBP1D)
CC       [MIM:229700]: An autosomal recessive metabolic disorder
CC       characterized by impaired gluconeogenesis, and episodes of
CC       hypoglycemia and metabolic acidosis that can be lethal in newborn
CC       infants or young children. {ECO:0000269|PubMed:12126934,
CC       ECO:0000269|PubMed:25601412, ECO:0000269|PubMed:9382095}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- SIMILARITY: Belongs to the FBPase class 1 family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAC50207.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/fbp1/";
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Fructose bisphosphatase entry;
CC       URL="https://en.wikipedia.org/wiki/Fructose_bisphosphatase";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M19922; AAA35517.1; -; mRNA.
DR   EMBL; L10320; AAA35817.1; -; mRNA.
DR   EMBL; D26054; BAA05051.1; -; mRNA.
DR   EMBL; D26055; BAA05052.1; -; mRNA.
DR   EMBL; D26056; BAA05053.1; -; mRNA.
DR   EMBL; U21931; AAC50207.1; ALT_SEQ; Genomic_DNA.
DR   EMBL; U21925; AAC50207.1; JOINED; Genomic_DNA.
DR   EMBL; U21926; AAC50207.1; JOINED; Genomic_DNA.
DR   EMBL; U21927; AAC50207.1; JOINED; Genomic_DNA.
DR   EMBL; U21929; AAC50207.1; JOINED; Genomic_DNA.
DR   EMBL; U21930; AAC50207.1; JOINED; Genomic_DNA.
DR   EMBL; AF073475; AAC25774.1; -; mRNA.
DR   EMBL; AK223395; BAD97115.1; -; mRNA.
DR   EMBL; AY866483; AAW34363.1; -; Genomic_DNA.
DR   EMBL; AL161728; CAH72692.1; -; Genomic_DNA.
DR   EMBL; BC012927; AAH12927.1; -; mRNA.
DR   EMBL; U47919; AAA89098.1; -; mRNA.
DR   EMBL; U47918; AAA89097.1; -; mRNA.
DR   CCDS; CCDS6712.1; -.
DR   PIR; A46666; A46666.
DR   RefSeq; NP_000498.2; NM_000507.3.
DR   RefSeq; NP_001121100.1; NM_001127628.1.
DR   UniGene; Hs.494496; -.
DR   PDB; 1FTA; X-ray; 2.30 A; A/B/C/D=2-338.
DR   PDB; 2FHY; X-ray; 2.95 A; A/D/H/L=1-338.
DR   PDB; 2FIE; X-ray; 2.81 A; A/D/H/L=1-338.
DR   PDB; 2FIX; X-ray; 3.50 A; A/D/H/L=1-338.
DR   PDB; 2JJK; X-ray; 2.00 A; A/B/C/D=1-338.
DR   PDB; 2VT5; X-ray; 2.20 A; A/B/C/D/E/F/G/H=1-338.
DR   PDB; 2WBB; X-ray; 2.22 A; A/B/C/D/E/F/G/H=1-338.
DR   PDB; 2WBD; X-ray; 2.40 A; A/B/C/D/E/F/G/H=1-338.
DR   PDB; 2Y5K; X-ray; 2.10 A; A/B/C/D=1-338.
DR   PDB; 2Y5L; X-ray; 2.20 A; A/B/C/D/E/F/G/H=1-338.
DR   PDB; 3A29; X-ray; 2.60 A; A/B/C/D=2-338.
DR   PDB; 3KBZ; X-ray; 2.45 A; A/B/C/D=2-338.
DR   PDB; 3KC0; X-ray; 2.80 A; A/B/C/D=2-338.
DR   PDB; 3KC1; X-ray; 2.25 A; A/B/C/D=2-338.
DR   PDB; 4MJO; X-ray; 2.40 A; A/B/C/D/E/F/G/H=1-338.
DR   PDB; 5LDZ; X-ray; 2.20 A; A/B/C/D/E/F=1-338.
DR   PDBsum; 1FTA; -.
DR   PDBsum; 2FHY; -.
DR   PDBsum; 2FIE; -.
DR   PDBsum; 2FIX; -.
DR   PDBsum; 2JJK; -.
DR   PDBsum; 2VT5; -.
DR   PDBsum; 2WBB; -.
DR   PDBsum; 2WBD; -.
DR   PDBsum; 2Y5K; -.
DR   PDBsum; 2Y5L; -.
DR   PDBsum; 3A29; -.
DR   PDBsum; 3KBZ; -.
DR   PDBsum; 3KC0; -.
DR   PDBsum; 3KC1; -.
DR   PDBsum; 4MJO; -.
DR   PDBsum; 5LDZ; -.
DR   ProteinModelPortal; P09467; -.
DR   SMR; P09467; -.
DR   BioGrid; 108497; 28.
DR   DIP; DIP-46677N; -.
DR   IntAct; P09467; 37.
DR   MINT; MINT-3006780; -.
DR   STRING; 9606.ENSP00000364475; -.
DR   BindingDB; P09467; -.
DR   ChEMBL; CHEMBL3975; -.
DR   DrugBank; DB08484; 4-AMINO-N-[(2-SULFANYLETHYL)CARBAMOYL]BENZENESULFONAMIDE.
DR   DrugBank; DB00131; Adenosine monophosphate.
DR   DrugBank; DB04493; Fructose-6-Phosphate.
DR   DrugBank; DB05053; MB07803.
DR   DrugBank; DB04175; Mdl-29951.
DR   DEPOD; P09467; -.
DR   iPTMnet; P09467; -.
DR   PhosphoSitePlus; P09467; -.
DR   BioMuta; FBP1; -.
DR   DMDM; 311033495; -.
DR   EPD; P09467; -.
DR   MaxQB; P09467; -.
DR   PaxDb; P09467; -.
DR   PeptideAtlas; P09467; -.
DR   PRIDE; P09467; -.
DR   DNASU; 2203; -.
DR   Ensembl; ENST00000375326; ENSP00000364475; ENSG00000165140.
DR   Ensembl; ENST00000415431; ENSP00000408025; ENSG00000165140.
DR   GeneID; 2203; -.
DR   KEGG; hsa:2203; -.
DR   UCSC; uc004auw.5; human.
DR   CTD; 2203; -.
DR   DisGeNET; 2203; -.
DR   GeneCards; FBP1; -.
DR   H-InvDB; HIX0008191; -.
DR   HGNC; HGNC:3606; FBP1.
DR   HPA; CAB033869; -.
DR   HPA; HPA005857; -.
DR   HPA; HPA012513; -.
DR   MalaCards; FBP1; -.
DR   MIM; 229700; phenotype.
DR   MIM; 611570; gene.
DR   neXtProt; NX_P09467; -.
DR   OpenTargets; ENSG00000165140; -.
DR   Orphanet; 348; Fructose-1,6-bisphosphatase deficiency.
DR   PharmGKB; PA28018; -.
DR   eggNOG; KOG1458; Eukaryota.
DR   eggNOG; COG0158; LUCA.
DR   GeneTree; ENSGT00390000015513; -.
DR   HOGENOM; HOG000191265; -.
DR   HOVERGEN; HBG005627; -.
DR   InParanoid; P09467; -.
DR   KO; K03841; -.
DR   OMA; FNYIAAK; -.
DR   OrthoDB; EOG091G0AZP; -.
DR   PhylomeDB; P09467; -.
DR   TreeFam; TF314824; -.
DR   BioCyc; MetaCyc:HS09189-MONOMER; -.
DR   BRENDA; 3.1.3.11; 2681.
DR   Reactome; R-HSA-70263; Gluconeogenesis.
DR   SABIO-RK; P09467; -.
DR   UniPathway; UPA00138; -.
DR   ChiTaRS; FBP1; human.
DR   EvolutionaryTrace; P09467; -.
DR   GenomeRNAi; 2203; -.
DR   PRO; PR:P09467; -.
DR   Proteomes; UP000005640; Chromosome 9.
DR   Bgee; ENSG00000165140; -.
DR   CleanEx; HS_FBP1; -.
DR   ExpressionAtlas; P09467; baseline and differential.
DR   Genevisible; P09467; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; ISS:UniProtKB.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0016208; F:AMP binding; IDA:UniProtKB.
DR   GO; GO:0042132; F:fructose 1,6-bisphosphate 1-phosphatase activity; IDA:UniProtKB.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0046872; F:metal ion binding; IMP:UniProtKB.
DR   GO; GO:0048029; F:monosaccharide binding; ISS:UniProtKB.
DR   GO; GO:0035690; P:cellular response to drug; IDA:UniProtKB.
DR   GO; GO:0071286; P:cellular response to magnesium ion; IDA:UniProtKB.
DR   GO; GO:0016311; P:dephosphorylation; IDA:UniProtKB.
DR   GO; GO:0030388; P:fructose 1,6-bisphosphate metabolic process; IBA:GO_Central.
DR   GO; GO:0006002; P:fructose 6-phosphate metabolic process; IDA:UniProtKB.
DR   GO; GO:0006000; P:fructose metabolic process; TAS:ProtInc.
DR   GO; GO:0006094; P:gluconeogenesis; IMP:UniProtKB.
DR   GO; GO:0030308; P:negative regulation of cell growth; IDA:UniProtKB.
DR   GO; GO:0045820; P:negative regulation of glycolytic process; IDA:UniProtKB.
DR   GO; GO:0046580; P:negative regulation of Ras protein signal transduction; IDA:UniProtKB.
DR   GO; GO:0051289; P:protein homotetramerization; IDA:UniProtKB.
DR   GO; GO:0006111; P:regulation of gluconeogenesis; IMP:UniProtKB.
DR   GO; GO:0005986; P:sucrose biosynthetic process; IBA:GO_Central.
DR   CDD; cd00354; FBPase; 1.
DR   HAMAP; MF_01855; FBPase_class1; 1.
DR   InterPro; IPR000146; FBPase_class-1.
DR   InterPro; IPR033391; FBPase_N.
DR   InterPro; IPR028343; FBPtase.
DR   InterPro; IPR020548; Fructose_bisphosphatase_AS.
DR   PANTHER; PTHR11556; PTHR11556; 1.
DR   Pfam; PF00316; FBPase; 1.
DR   PIRSF; PIRSF500210; FBPtase; 1.
DR   PIRSF; PIRSF000904; FBPtase_SBPase; 1.
DR   PRINTS; PR00115; F16BPHPHTASE.
DR   PROSITE; PS00124; FBPASE; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Allosteric enzyme; Carbohydrate metabolism;
KW   Complete proteome; Direct protein sequencing; Disease mutation;
KW   Gluconeogenesis; Hydrolase; Magnesium; Metal-binding; Phosphoprotein;
KW   Polymorphism; Reference proteome.
FT   INIT_MET      1      1       Removed. {ECO:0000250|UniProtKB:P00637,
FT                                ECO:0000269|PubMed:8387495}.
FT   CHAIN         2    338       Fructose-1,6-bisphosphatase 1.
FT                                /FTId=PRO_0000200498.
FT   NP_BIND      18     22       AMP. {ECO:0000269|PubMed:7809062}.
FT   NP_BIND      28     32       AMP. {ECO:0000269|PubMed:7809062}.
FT   NP_BIND     113    114       AMP. {ECO:0000269|PubMed:7809062}.
FT   REGION      122    125       Substrate binding.
FT   REGION      213    216       Substrate binding.
FT   REGION      244    249       Substrate binding.
FT   REGION      275    277       Substrate binding.
FT   METAL        69     69       Magnesium 1. {ECO:0000250}.
FT   METAL        98     98       Magnesium 1. {ECO:0000250}.
FT   METAL        98     98       Magnesium 2.
FT   METAL       119    119       Magnesium 2.
FT   METAL       119    119       Magnesium 3.
FT   METAL       121    121       Magnesium 2; via carbonyl oxygen.
FT   METAL       122    122       Magnesium 3.
FT   METAL       281    281       Magnesium 3.
FT   BINDING     141    141       AMP. {ECO:0000269|PubMed:7809062}.
FT   BINDING     265    265       Substrate.
FT   MOD_RES       2      2       N-acetylalanine.
FT                                {ECO:0000250|UniProtKB:P00637}.
FT   MOD_RES     151    151       N6-succinyllysine.
FT                                {ECO:0000250|UniProtKB:Q9QXD6}.
FT   MOD_RES     216    216       Phosphotyrosine.
FT                                {ECO:0000250|UniProtKB:Q9QXD6}.
FT   MOD_RES     245    245       Phosphotyrosine.
FT                                {ECO:0000250|UniProtKB:Q9QXD6}.
FT   MOD_RES     265    265       Phosphotyrosine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   VARIANT     158    158       R -> W (in FBP1D; unknown pathological
FT                                significance; dbSNP:rs766005419).
FT                                {ECO:0000269|PubMed:25601412}.
FT                                /FTId=VAR_075492.
FT   VARIANT     164    164       G -> S (in FBP1D; dbSNP:rs121918188).
FT                                {ECO:0000269|PubMed:9382095}.
FT                                /FTId=VAR_002380.
FT   VARIANT     177    177       A -> D (in FBP1D; dbSNP:rs121918189).
FT                                {ECO:0000269|PubMed:9382095}.
FT                                /FTId=VAR_002381.
FT   VARIANT     194    194       F -> S (in FBP1D; dbSNP:rs121918191).
FT                                {ECO:0000269|PubMed:12126934}.
FT                                /FTId=VAR_038812.
FT   VARIANT     218    218       R -> K (in dbSNP:rs1769259).
FT                                {ECO:0000269|PubMed:10222032,
FT                                ECO:0000269|PubMed:2842796,
FT                                ECO:0000269|PubMed:7558035,
FT                                ECO:0000269|PubMed:8135811,
FT                                ECO:0000269|PubMed:8387495,
FT                                ECO:0000269|Ref.6, ECO:0000269|Ref.7}.
FT                                /FTId=VAR_022212.
FT   VARIANT     233    233       F -> I (in dbSNP:rs2297085).
FT                                {ECO:0000269|Ref.7}.
FT                                /FTId=VAR_022213.
FT   VARIANT     255    255       R -> L (in dbSNP:rs28369761).
FT                                {ECO:0000269|Ref.7}.
FT                                /FTId=VAR_022214.
FT   VARIANT     284    284       P -> R (in FBP1D; dbSNP:rs121918192).
FT                                {ECO:0000269|PubMed:12126934}.
FT                                /FTId=VAR_038813.
FT   VARIANT     325    325       V -> A. {ECO:0000269|PubMed:9382095}.
FT                                /FTId=VAR_002382.
FT   MUTAGEN      70     70       Q->E: Increased affinity towards Ca(2+)
FT                                and Mg(2+).
FT                                {ECO:0000269|PubMed:17350621}.
FT   MUTAGEN     119    119       D->A: Reduced activity.
FT                                {ECO:0000269|PubMed:8387495}.
FT   MUTAGEN     122    122       D->A: Reduced activity.
FT                                {ECO:0000269|PubMed:8387495}.
FT   CONFLICT    215    215       G -> A (in Ref. 2; AAA35817 and 5;
FT                                AAC25774). {ECO:0000305}.
FT   CONFLICT    337    337       A -> G (in Ref. 5; AAC25774).
FT                                {ECO:0000305}.
FT   HELIX        14     24       {ECO:0000244|PDB:2JJK}.
FT   HELIX        30     49       {ECO:0000244|PDB:2JJK}.
FT   TURN         50     53       {ECO:0000244|PDB:2JJK}.
FT   HELIX        54     57       {ECO:0000244|PDB:2JJK}.
FT   TURN         58     61       {ECO:0000244|PDB:2JJK}.
FT   HELIX        74     87       {ECO:0000244|PDB:2JJK}.
FT   TURN         88     90       {ECO:0000244|PDB:2Y5K}.
FT   STRAND       92     97       {ECO:0000244|PDB:2JJK}.
FT   HELIX       108    110       {ECO:0000244|PDB:2JJK}.
FT   STRAND      111    122       {ECO:0000244|PDB:2JJK}.
FT   HELIX       124    129       {ECO:0000244|PDB:2JJK}.
FT   STRAND      133    141       {ECO:0000244|PDB:2JJK}.
FT   STRAND      144    147       {ECO:0000244|PDB:2Y5L}.
FT   HELIX       150    153       {ECO:0000244|PDB:2JJK}.
FT   HELIX       157    159       {ECO:0000244|PDB:2JJK}.
FT   STRAND      161    178       {ECO:0000244|PDB:2JJK}.
FT   STRAND      181    188       {ECO:0000244|PDB:2JJK}.
FT   TURN        189    192       {ECO:0000244|PDB:2JJK}.
FT   STRAND      193    198       {ECO:0000244|PDB:2JJK}.
FT   STRAND      208    212       {ECO:0000244|PDB:2JJK}.
FT   HELIX       214    219       {ECO:0000244|PDB:2JJK}.
FT   HELIX       222    232       {ECO:0000244|PDB:2JJK}.
FT   STRAND      235    237       {ECO:0000244|PDB:2Y5K}.
FT   HELIX       249    259       {ECO:0000244|PDB:2JJK}.
FT   STRAND      262    265       {ECO:0000244|PDB:2JJK}.
FT   STRAND      269    271       {ECO:0000244|PDB:2WBD}.
FT   STRAND      275    277       {ECO:0000244|PDB:2JJK}.
FT   TURN        278    281       {ECO:0000244|PDB:2JJK}.
FT   HELIX       282    291       {ECO:0000244|PDB:2JJK}.
FT   STRAND      295    297       {ECO:0000244|PDB:2JJK}.
FT   STRAND      299    302       {ECO:0000244|PDB:2JJK}.
FT   HELIX       303    305       {ECO:0000244|PDB:2JJK}.
FT   STRAND      317    321       {ECO:0000244|PDB:2JJK}.
FT   HELIX       322    334       {ECO:0000244|PDB:2JJK}.
SQ   SEQUENCE   338 AA;  36842 MW;  B3D270BCBB358B71 CRC64;
     MADQAPFDTD VNTLTRFVME EGRKARGTGE LTQLLNSLCT AVKAISSAVR KAGIAHLYGI
     AGSTNVTGDQ VKKLDVLSND LVMNMLKSSF ATCVLVSEED KHAIIVEPEK RGKYVVCFDP
     LDGSSNIDCL VSVGTIFGIY RKKSTDEPSE KDALQPGRNL VAAGYALYGS ATMLVLAMDC
     GVNCFMLDPA IGEFILVDKD VKIKKKGKIY SLNEGYARDF DPAVTEYIQR KKFPPDNSAP
     YGARYVGSMV ADVHRTLVYG GIFLYPANKK SPNGKLRLLY ECNPMAYVME KAGGMATTGK
     EAVLDVIPTD IHQRAPVILG SPDDVLEFLK VYEKHSAQ
//
